Results from the pivotal phase III ARCADIA 1 and 2 and OLYMPIA 1 studies evaluating the safety and efficacy of nemolizumab in moderate to severe atopic dermatitis and prurigo nodularis will be presented for the first time as late-breaking abstracts.1,2
New data on trifarotene from the phase IV START study showing positive outcomes, patient satisfaction and patient compliance for risk of atrophic acne scarring will be presented. Data from the phase IV LEAP study in post-inflammatory hyperpigmentation (PIH) will also be shared.3,4
In total, Galderma will sponsor two symposia and present 15 abstracts with data on sensitive skin, healthy skin ageing and diversity and inclusion in dermatology.
ZUG, Switzerland--(BUSINESS WIRE)--Galderma, the emerging pure-play dermatology category leader, announced today it will be showcasing updates from across its broad and innovative dermatology portfolio at the 32nd European Academy of Dermatology and Venereology (EADV) congress in Berlin, October 11-14, 2023. For more than 40 years, Galderma has focused exclusively on delivering advances in dermatology, and its extensive presence at this year’s congress underlines the true impact of its industry-leading expertise and ongoing commitment to cutting-edge science, brands and services.
|
“We’re so excited to share such an extensive range of new data at EADV this year, and for another opportunity to engage with the community of physicians attending. We look forward to exchanging knowledge and insights that will help us to push the boundaries of scientific innovation together.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
|
|
